15 Jan 2015 Posted in ABPI statement By Press Office
The UK is a global leader in medicines manufacturing and the sector has the ability to transform the lives of patients through the research, development and delivery of new and innovative medicines. Part of the UK’s success in medicines manufacturing is having a supportive and progressive regulator in the MHRA.
Last year the Association of the British Pharmaceutical Industry (ABPI) and the BioIndustry Association (BIA) set up and launched the Medicines Manufacturing Industry Partnership (MMIP) to create and promote a vibrant medicines manufacturing sector in the UK. We have been working closely with MHRA to develop a series of case studies that demonstrate the range of support and guidance MHRA can offer companies as they develop new products and technologies. This case study – the second to be published by the MHRA - is another great example of how UK medicines manufacturers like OxSonics are using this support to develop a new generation of devices and treatments that will improve the outcomes of patients.
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811